A Randomised, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled, Multi-Centre, Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 (0.3, 1, 3, 10 mg) and Placebo on Stopping Preterm Labour and Uterine Contractions in Pregnant Women With Advanced Gestational Age.

Trial Profile

A Randomised, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled, Multi-Centre, Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 (0.3, 1, 3, 10 mg) and Placebo on Stopping Preterm Labour and Uterine Contractions in Pregnant Women With Advanced Gestational Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2011

At a glance

  • Drugs Barusiban (Primary)
  • Indications Preterm labour
  • Focus Therapeutic Use
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2009 Results published in the American Journal of Obstetrics and Gynecology.
    • 20 May 2009 Actual end date changed from Jun 2006 to Aug 2006 as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual patient number (163) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top